A Phase II Randomized Trial for Early-stage Squamous Cell Carcinoma of the Oropharynx: Radiation Therapy vs Trans-oral Robotic Surgery (ORATOR)

Official Title

A Phase II Randomized Trial for Early-stage Squamous Cell Carcinoma of the Oropharynx: Radiation Therapy vs Trans-oral Robotic Surgery (ORATOR)

Summary:

The historical standard treatment for early-stage squamous cell carcinoma of the oropharynx is radiation therapy. Some patients require chemotherapy with the radiation, and some patients require surgery if the tumour or lymph nodes have not responded after radiation. This study will compare radiation therapy with a new surgical treatment called transoral robotic surgery (TORS). TORS is a new surgical approach using a robot to assist the surgeon in removing the tumour, potentially with fewer side effects than older surgical techniques.

Trial Description

Primary Outcome:

  • Quality of Life
Secondary Outcome:
  • Overall Survival
  • Progression-free survival
  • Quality of life at other time points
  • Toxicity
  • Swallowing Function

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society